The treatment of cancer cells with DNMT or HDAC inhibitors results in hypomethylation and hyperacetylation that can restore normal methylation and acetylation patterns, respectively, leading to the silencing or activation of genes crucial for normal cell functions (Yoo and Jones, 2006). This evidence concerns the gene DNMT1 and cancer.